5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid | 1220950-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid
• CAS: 1220950-89-9
• 化学式: C₁₂H₁₀ClNO₂
• 分子量: 235.67
• InChiKey: YQZXIBNRMMCZJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  20(S)-3β-o-(1-chloracetyl)panaxadiol 、 5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以69 %的产率得到2-(((3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)hexadecahydro-1H-cyclopenta[α]phenanthren-3-yl)oxy) 2-oxoethyl-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylate
  参考文献：
  名称：

  具有吡唑和吡咯结构的人参二醇酯衍生物作为HIF-1α抑制剂的合成及生物学评价

  摘要：

  缺氧诱导因子1α（HIF-1α）在多种肿瘤患者中过度表达，在调节肿瘤细胞缺氧反应中发挥重要作用。因此，其抑制剂已成为多种癌症的治疗靶点之一。合成了两个系列含有吡唑()和吡咯()结构的人参二醇(PD)酯衍生物，并评价了它们的HIF-1α抑制活性。在所有目标化合物中，化合物 、 和 (IC = 8.7010.44 μM) 显示出比 PD (IC = 13.35 μM) 更好的 HIF-1α 抑制活性。这些化合物均未表现出高于 100 μM 的细胞毒性，并以剂量​​依赖性方式抑制 HIF-1α 转录。这些化合物表现出良好的抗肿瘤活性，为PD酯衍生物的进一步设计和活性研究提供了先导化合物。

  DOI：

  10.1016/j.fitote.2024.106052
• 作为产物：
  描述：

  2-乙酰基-4-(4-氯苯基)-4-氧代丁酸乙酯 在 ammonium acetate 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 18.0h， 生成 5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid
  参考文献：
  名称：

  具有吡唑和吡咯结构的人参二醇酯衍生物作为HIF-1α抑制剂的合成及生物学评价

  摘要：

  缺氧诱导因子1α（HIF-1α）在多种肿瘤患者中过度表达，在调节肿瘤细胞缺氧反应中发挥重要作用。因此，其抑制剂已成为多种癌症的治疗靶点之一。合成了两个系列含有吡唑()和吡咯()结构的人参二醇(PD)酯衍生物，并评价了它们的HIF-1α抑制活性。在所有目标化合物中，化合物 、 和 (IC = 8.7010.44 μM) 显示出比 PD (IC = 13.35 μM) 更好的 HIF-1α 抑制活性。这些化合物均未表现出高于 100 μM 的细胞毒性，并以剂量​​依赖性方式抑制 HIF-1α 转录。这些化合物表现出良好的抗肿瘤活性，为PD酯衍生物的进一步设计和活性研究提供了先导化合物。

  DOI：

  10.1016/j.fitote.2024.106052

文献信息

• ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS
  申请人：Lee Jinhwa

  公开号：US20110178091A1

  公开（公告）日：2011-07-21

  The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.

  本发明涉及一种新的芳基哌嗪含有吡咯3-羧酰胺衍生物的化合物（I），或其药学上可接受的盐，用于预防或治疗抑郁症。本发明还提供了制备芳基哌嗪含有吡咯3-羧酰胺衍生物或其药学上可接受的盐的方法，包括含有它们的药物组合物，以及预防或治疗抑郁症的方法。
• Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor
  作者：Hamid R. Hoveyda、Marie-Odile Roy、Sebastien Blanc、Sophie Noël、Joseph M. Salvino、Mark A. Ator、Graeme Fraser

  DOI：10.1016/j.bmcl.2011.02.033

  日期：2011.4

  A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled human tachykinin NK3 receptor (hNK3-R) is described. Preliminary profiling revealed poor plasma and metabolic stability for these structures in rodents. Further optimization efforts resulted in analogs with improved potency, stability, and pharmacokinetic properties as well as good brain permeability, for example, compounds 26 and 42. Unexpected cytotoxicity was observed in such N-Me pyrazole structures as compounds 41-42. (C) 2011 Elsevier Ltd. All rights reserved.
• Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant
  作者：Suk Youn Kang、Eun-Jung Park、Woo-Kyu Park、Hyun Jung Kim、Gildon Choi、Myung Eun Jung、Hee Jeong Seo、Min Ju Kim、Ae Nim Pae、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmc.2010.06.037

  日期：2010.8

  In the continuing search for novel compounds targeting serotonin 5-HT2A, 5-HT2C, and serotonin transporter, new arylpiperazine-containing pyrrole 3-carboxamide derivatives were synthesized and evaluated. Based on the lead reported previously, structural modifications regarding N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-1,2-dimethyl-5-phenyl-1H-pyrrole-3-carboxamide 5, were accomplished for improvements in not only binding affinity against serotonin receptors and transporter, but also in hERG channel inhibition. Along the line, both the forced swimming tests and spontaneous locomotor activity tests were performed to distinguish between antidepressant activity and false positive results. As potential antidepressant agents, both 2,4-dimethyl-5-phenyl-1H-pyrrole-3-carboxamide and 5-tert-butyl-2-methyl-1H-pyrrole-3-carboxamide derivatives exhibited favorable in vitro and in vivo activities, warranting further investigation around these scaffolds. (C) 2010 Elsevier Ltd. All rights reserved.
• US8895558B2
  申请人：——

  公开号：US8895558B2

  公开（公告）日：2014-11-25
• [EN] ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS<br/>[FR] DÉRIVÉS DE PYRROLE 3-CARBOXAMIDE CONTENANT DE L'ARYLPIPÉRAZINE POUR LE TRAITEMENT DE TROUBLES DÉPRESSIFS
  申请人：GREEN CROSS CORP

  公开号：WO2010038948A2

  公开（公告）日：2010-04-08

  The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.